Bone Biologics Files Routine 8-K on Jan 9 Event
Ticker: BBLGW · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, current-report
TL;DR
**Bone Biologics filed a standard 8-K, no major news here.**
AI Summary
Bone Biologics Corp. filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024. This filing is a standard current report and does not disclose specific financial transactions, new agreements, or material changes. For investors, this filing is largely administrative and does not provide new information that would immediately impact investment decisions, as it primarily confirms the company's basic identifying information and the date of the reportable event.
Why It Matters
This filing is a routine administrative update, indicating no immediate material changes or significant events for Bone Biologics Corp. that would directly affect its stock price or investor sentiment.
Risk Assessment
Risk Level: low — This 8-K is a routine filing with no disclosed material events, posing minimal risk to investors.
Analyst Insight
Given this is a routine administrative filing with no material news, a smart investor would not take immediate action based solely on this 8-K. It's important to monitor for subsequent filings that might contain substantive updates.
Key Players & Entities
- Bone Biologics Corporation (company) — the registrant filing the 8-K
- January 9, 2024 (date) — date of earliest event reported
- January 10, 2024 (date) — date the 8-K was filed
- 001-40899 (other) — Commission File Number
- 42-1743430 (other) — IRS Employer Identification No.
FAQ
What is the purpose of this 8-K filing by Bone Biologics Corp.?
This 8-K filing is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' and appears to be a routine administrative filing, as it does not detail specific material events beyond the date of the earliest event reported, which was January 9, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 9, 2024, as stated under 'Date of Report (Date of earliest event reported): January 9, 2024'.
What is the state of incorporation for Bone Biologics Corporation?
Bone Biologics Corporation is incorporated in Delaware, as indicated by 'Delaware (State or other jurisdiction of incorporation)' in the filing.
What is the business address of Bone Biologics Corporation?
The business address of Bone Biologics Corporation is 2 Burlington Woods Drive, Suite 100, Burlington, MA 01803, as listed in the filing.
Does this 8-K filing indicate any specific financial transactions or new agreements?
No, this 8-K filing does not indicate any specific financial transactions, new agreements, or other material events. It is a standard current report that primarily confirms basic company information and the date of the reportable event.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2024-01-10 08:15:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex99-1.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-001892.txt ( ) — 281KB
- bblg-20240109.xsd (EX-101.SCH) — 4KB
- bblg-20240109_def.xml (EX-101.DEF) — 26KB
- bblg-20240109_lab.xml (EX-101.LAB) — 36KB
- bblg-20240109_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: January 10, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer